HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026?

The article compares HeartFlow and NovoCure as long-term investments, highlighting stronger revenue scale at NovoCure ($655.4M FY2025 vs. $176M for HeartFlow) and a lower valuation (P/S 2.5x vs. 15.5x). Both remain unprofitable, with negative free cash flow and expected profitability only around 2028, while HeartFlow faces DOJ scrutiny and patent litigation and NovoCure carries reimbursement, partnership, and geopolitical risks. The author concludes NovoCure offers the better risk-to-reward profile.

Analysis

The market is implicitly paying up for HTFL’s option value on workflow automation, but the current setup still looks like a classic “great product, premature valuation” story. The business has an easier path to penetration than a therapy company because the buyer is a hospital/physician network rather than a patient adhering to treatment, but that also means reimbursement scrutiny can reprice the whole model faster than adoption can compound. In other words, HTFL’s upside is tied to broader diagnostic standardization, while its downside is concentrated in a few policy and legal decision points.

NVCR has the better near-term operating visibility because it already has meaningful commercial scale and a more diversified end-market footprint across geographies and indications. The second-order issue is that this scale is not yet translating into operating leverage, so every incremental reimbursement delay or partner misstep in China has an outsized effect on cash burn. The balance of risk is therefore less about “will the product work?” and more about “how long can capital and channel support bridge to a self-funding model?”

Contrarian angle: the consensus may be underestimating how much valuation matters when neither name is close to positive FCF. HTFL’s premium multiple leaves little room for reimbursement compression or litigation overhang, while NVCR’s lower multiple gives it a wider margin for execution errors even though its business quality is less optionality-rich. The cleanest setup is not a blanket long on either name, but a relative-value expression favoring the lower-multiple, already-scaled asset unless upcoming catalyst data shows HTFL can reaccelerate adoption without incremental legal or pricing risk.

Key Decisions for Investors

• Prefer NVCR over HTFL on a 6-12 month horizon via a long NVCR / short HTFL pair: NVCR has the better downside cushion from valuation, while HTFL’s multiple leaves little room for reimbursement or legal disappointment.
• If using options, consider selling HTFL downside put spreads into strength rather than owning outright equity; the setup is high-variance and the valuation already prices in a cleaner commercialization path than the current policy backdrop supports.
• Own NVCR only as a catalyst-driven position sized for binary reimbursement/partner news over the next 3-6 months; the reward is moderate upside from multiple expansion, but the thesis breaks quickly if China or hospital contracting slips.
• Avoid initiating new long HTFL at elevated multiples until there is evidence of margin inflection or regulatory clarity; the risk/reward is skewed because most of the upside depends on execution that is still 12-24 months away.
• For risk-tolerant accounts, express the view through a basket trade: long NVCR against a smaller short in HTFL, targeting relative multiple convergence rather than absolute sector beta.